Abstract
Typhoid fever remains a serious public health problem. We have developed a vaccine from Salmonella enterica serovar typhi (S. typhi) outer-membrane proteins (OMPs) known as porins. A single subcutaneous dose of 10 microg of porins induced a five-fold (P = 0.05) seroconversion index consisting of IgM and IgG at 7 and 15 days after vaccination as well as the production of IgG1 and IgG2 isotypes. The porins-based vaccine induced a two-fold increase (P = 0.05) in bactericidal titres in volunteers, whom also developed a T-cell response characterized by the production of interferon-gamma (INF-gamma). Side effects after vaccination were mild and transient. The data showed that our S. typhi porins-based candidate vaccine is safe and immunogenic in healthy humans.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antibody Formation / immunology*
-
Antibody Specificity / immunology
-
Blood Bactericidal Activity / immunology
-
Cell Proliferation / drug effects
-
Chromatography, Gel
-
Double-Blind Method
-
Electrophoresis, Polyacrylamide Gel
-
Enzyme-Linked Immunosorbent Assay
-
Escherichia coli / chemistry
-
Escherichia coli / immunology
-
Humans
-
Immunity, Cellular / immunology*
-
Immunoglobulin G / blood
-
Immunoglobulin G / immunology
-
Immunoglobulin M / blood
-
Immunoglobulin M / immunology
-
Interferon-gamma / metabolism
-
Interleukin-4 / metabolism
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / immunology
-
Leukocytes, Mononuclear / metabolism
-
Male
-
Porins / immunology
-
Porins / isolation & purification
-
Porins / pharmacology
-
Salmonella typhi / chemistry
-
Salmonella typhi / immunology*
-
Typhoid Fever / immunology
-
Typhoid Fever / prevention & control*
-
Vaccination / adverse effects
-
Vaccination / methods*
Substances
-
Immunoglobulin G
-
Immunoglobulin M
-
Porins
-
Interleukin-4
-
Interferon-gamma